STOCK TITAN

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
earnings

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens on November 9, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on November 9, 2021, to provide a business update and discuss the financial results.

Tuesday, November 9, 8:30 a.m. ET

Domestic: +1 833-979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3435370/D4A161A628859FC2957F63CBDDD69D3A
Conference ID: 6362837

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com.

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

Marinus Pharmaceuticals Inc

NASDAQ:MRNS

MRNS Rankings

MRNS Latest News

MRNS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing

About MRNS

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides